RESEARKA

This synthesis addresses these gaps by systematically mapping the evidence for Carnosine anti glycation across outcome classes, distinguishing clinical from mechanistic findings, and explicitly weighting the tensions that pervade the literature. Across 38 curated reference papers, positive signals appear in frailty and safety-comorbidity domains, while negative or null findings dominate cardiometabolic and contextual-outcome classes, with cross-study disagreements identified across outcome pairings. The structured approach separates the question of mechanistic plausibility — which appears well-supported by in-vitro and observational data — from clinical efficacy, which remains uncertain and context-dependent. By organizing evidence according to outcome class, directness, and effect direction, rather than presenting an exhaustive inventory of individual studies, this synthesis aims to clarify where Carnosine anti glycation evidence converges, where it diverges, and what specific gaps future trials must address. The central question — whether Carnosine anti glycation represents a viable anti-aging intervention — cannot be answered by any single study; it requires the kind of cross-domain integration attempted here, bounded by the recognition that the mechanistic-to-clinical translation remains incomplete.

Citation Support

• source_1 Movahedian 2025
• source_2 Kopytek 2025
• source_3 Kabthymer 2024
• source_4 Li 2025
• source_5 Dahlen 2025